Kolexia
Dorvaux Veronique Oncologie médicale
Dorvaux Veronique
Oncologie médicale
Hôpital Mercy
Ars-Laquenexy, France
74 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Lymphomes Tumeurs à plasmocytes Leucémies Lymphome à cellules du manteau Leucémie aigüe myéloïde Aberrations des chromosomes Amyloïdose Amylose à chaine légère d'immunoglobuline

Collaborateurs

Voir plus
Caillot Denis
Caillot Denis
Clinique Mutualiste Benigne Joly, Talant, France
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Carassou Philippe
Carassou Philippe
Hia Legouest, Metz, France
Perrot Aurore
Perrot Aurore
Oncopole Toulouse, Toulouse, France

Industries

Voir plus
Janssen
10 collaboration(s)
Dernière en 2023
Novartis
8 collaboration(s)
Dernière en 2023
Amgen
6 collaboration(s)
Dernière en 2023
Sanofi
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica   30 novembre 2023
Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes
65th ASH Annual Meeting Abstracts   02 novembre 2023
APAER_H: Adapted Physical Activity and Relaxation by Biofeedback in Patients With Haematological Malignancy Admitted in Intensive Care unit_APAER_H Protocol
Essai Clinique (Centre Hospitalier Régional Metz-Thionville)   03 juillet 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Essai Clinique (Takeda Pharmaceutical)   07 février 2023
Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study.
American journal of hematology   01 janvier 2023
Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study
Annual Meeting Abstracts 2022   15 novembre 2022
IFM2014-02: IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma
Essai Clinique (Janssen)   17 mai 2022
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Blood   09 mai 2022
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Bone marrow transplantation   14 avril 2022